Pacer Advisors Inc. Cuts Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Pacer Advisors Inc. lowered its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 5.5% during the third quarter, HoldingsChannel reports. The fund owned 2,804,013 shares of the biopharmaceutical company’s stock after selling 163,562 shares during the period. Pacer Advisors Inc.’s holdings in Catalyst Pharmaceuticals were worth $55,744,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the company. GAMMA Investing LLC lifted its position in Catalyst Pharmaceuticals by 62.1% during the 3rd quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 681 shares during the period. nVerses Capital LLC acquired a new stake in shares of Catalyst Pharmaceuticals during the third quarter worth $50,000. CWM LLC boosted its holdings in shares of Catalyst Pharmaceuticals by 686.5% during the second quarter. CWM LLC now owns 4,066 shares of the biopharmaceutical company’s stock worth $63,000 after purchasing an additional 3,549 shares during the last quarter. Meeder Asset Management Inc. acquired a new position in Catalyst Pharmaceuticals in the second quarter valued at $70,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Catalyst Pharmaceuticals during the second quarter worth about $153,000. 79.22% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

CPRX has been the topic of a number of analyst reports. Stephens initiated coverage on Catalyst Pharmaceuticals in a research report on Monday. They set an “overweight” rating and a $35.00 target price on the stock. Truist Financial boosted their price objective on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a research report on Monday, November 11th. Citigroup boosted their price objective on Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. HC Wainwright restated a “buy” rating and issued a $30.00 target price on shares of Catalyst Pharmaceuticals in a research report on Friday, November 8th. Finally, StockNews.com raised Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 9th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $31.14.

Catalyst Pharmaceuticals Stock Performance

CPRX opened at $21.12 on Friday. The company has a fifty day moving average price of $21.09 and a two-hundred day moving average price of $18.47. Catalyst Pharmaceuticals, Inc. has a 52 week low of $13.00 and a 52 week high of $24.27. The firm has a market capitalization of $2.52 billion, a PE ratio of 17.90, a P/E/G ratio of 3.29 and a beta of 0.75.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.